The fastest-growing and largest of the 19 sized Pharmaceuticals markets worldwide, 2023 to 2033, with active clinical trials.
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Biosimilars | $36.9 Bn | $340.9 Bn | 24.9% | – |
| 2 | Cell Based Immunotherapy | $16.6 Bn | $131.6 Bn | 23% | – |
| 3 | Cannabidiol (CBD) | $22.1 Bn | $104.2 Bn | 16.8% | – |
| 4 | Cannabis | $33.9 Bn | $120.3 Bn | 13.5% | – |
| 5 | Atopic Dermatitis Drugs | $11.2 Bn | $35.5 Bn | 12.2% | – |
| 6 | Oncology/Cancer Drugs | $177 Bn | $396.5 Bn | 8.4% | – |
| 7 | Anti-Aging | $88.2 Bn | $192.2 Bn | 8.1% | – |
| 8 | Diabetes Management | $78 Bn | $154.9 Bn | 7.1% | – |
| 9 | Contraceptives Drugs | $25.2 Bn | $48.7 Bn | 6.8% | – |
| 10 | Cord Blood Banking Service | $1.9 Bn | $3.6 Bn | 6.5% | – |
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Oncology/Cancer Drugs | $177 Bn | $396.5 Bn | 8.4% | – |
| 2 | Anti-Aging | $88.2 Bn | $192.2 Bn | 8.1% | – |
| 3 | Diabetes Management | $78 Bn | $154.9 Bn | 7.1% | – |
| 4 | Gastrointestinal Drugs | $54 Bn | $84.7 Bn | 4.6% | – |
| 5 | Asthma & COPD Drugs | $49.5 Bn | $73.3 Bn | 4% | – |
| 6 | Biosimilars | $36.9 Bn | $340.9 Bn | 24.9% | – |
| 7 | Cannabis | $33.9 Bn | $120.3 Bn | 13.5% | – |
| 8 | HIV Drugs | $30 Bn | $52.7 Bn | 5.8% | – |
| 9 | Contraceptives Drugs | $25.2 Bn | $48.7 Bn | 6.8% | – |
| 10 | Cancer Supportive Care Drugs | $24.8 Bn | $39.3 Bn | 4.7% | – |
2033 values are projected from the 2023 size and the CAGR. Each market name opens its report. Active trials: recruiting, about to start or running.
Biosimilars grows fastest, at 24.9% a year from 2023 to 2033, ahead of Cell Based Immunotherapy (23%).
Oncology/Cancer Drugs is the largest, worth about $177 Bn in 2023 and $396.5 Bn by 2033 (projected).
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide.